Cargando…

Realizing the Potential for Recipient Immune Cells in Adoptive Immune Therapy

Detalles Bibliográficos
Autor principal:	Qazi, Sanjive
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006657/ https://www.ncbi.nlm.nih.gov/pubmed/27397512 http://dx.doi.org/10.1016/j.ebiom.2016.07.003

Ejemplares similares

Realizing the Potential of the Patient Perspective
por: Simon, Teresa A, et al.
Publicado: (2020)

Realizing the potential of organoids—an interview with Hans Clevers
por: Bartfeld, Sina
Publicado: (2021)

Promoting pancreatic β cell proliferation: A powerful key for realizing regenerative therapy for diabetes
por: Shimaya, Yukihiro, et al.
Publicado: (2022)

Practical problems may preclude realization of this proposal
por: Della Mea, Vincenzo
Publicado: (2000)

Realizing the right to health in Latin America, equitably
por: Villar Uribe, Manuela, et al.
Publicado: (2021)

The Multiple Realizability of Sentience in Living Systems and Beyond
por: Rouleau, Nicolas, et al.
Publicado: (2023)

ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma
por: Uckun, Fatih M., et al.
Publicado: (2022)

Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance
por: Uckun, Fatih M., et al.
Publicado: (2022)

Biological and Molecular Factors Predicting Response to Adoptive Cell Therapies in Cancer
por: Ferrer, Gerardo, et al.
Publicado: (2022)

Patient-reported outcomes in adoptive cell-therapy trials: mind the gap
por: Ghisoni, Eleonora, et al.
Publicado: (2022)

Adoptive Cell Therapy in Hepatocellular Carcinoma: A Review of Clinical Trials
por: Ozer, Muhammet, et al.
Publicado: (2023)

The opposite impact of Janus kinase inhibitor Ruxolitinib on the function of bone marrow mesenchymal stem cells and immune cells in acute GVHD recipients
por: Zeng, Defu
Publicado: (2023)

Stop stunting: Pakistan perspective on how this could be realized
por: Das, Jai K., et al.
Publicado: (2016)

The first step in utilizing immune-modulating therapies: immune status determination
por: Caldwell, Charles C, et al.
Publicado: (2011)

Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy
por: Wang, Ena, et al.
Publicado: (2020)

Adoptive transfer of immune cells from glaucomatous mice provokes retinal ganglion cell loss in recipients
por: Gramlich, Oliver W., et al.
Publicado: (2015)

Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Partially Realized Potential
por: Armstrong, Samantha A., et al.
Publicado: (2019)

Immune correlates of melanoma survival in adoptive cell therapy
por: Lee, Agnes Fermin, et al.
Publicado: (2013)

SYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia
por: Uckun, Fatih M., et al.
Publicado: (2014)

Upregulated Expression of ErbB1 in Diffuse Large B-Cell Lymphoma as a Predictor of Poor Overall Survival Outcome
por: Qazi, Sanjive, et al.
Publicado: (2023)

Computational Toxicology: Realizing the Promise of the Toxicity Testing in the 21st Century
por: Rusyn, Ivan, et al.
Publicado: (2010)

A commentary on cancer prevention and control in India: Priorities for realizing SDGs
por: Ramani, Vinod K., et al.
Publicado: (2023)

Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors
por: Mundra, Vatsala, et al.
Publicado: (2023)

Industrial chemistry and chemoecology are linked together to realize a modern and sustainable chemistry
por: Saling, Peter
Publicado: (2007)

An immune cocktail therapy to realize multiple boosting of the cancer-immunity cycle by combination of drug/gene delivery nanoparticles
por: Wu, Jiayan, et al.
Publicado: (2020)

Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy
por: Tourret, Marie, et al.
Publicado: (2021)

Immune cell labelling and tracking: implications for adoptive cell transfer therapies
por: Galli, Filippo, et al.
Publicado: (2021)

Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
por: Nixon, Andrew B., et al.
Publicado: (2019)

Adjuvants of Immunity : Harnessing Innate Immunity to Promote Adaptive Immunity
por: Bendelac, Albert, et al.
Publicado: (2002)

Treatment duration with immune-based therapies in Cancer: an enigma
por: Bantia, Shanta, et al.
Publicado: (2018)

Antibiotic therapy and outcome from immune-checkpoint inhibitors
por: Pinato, David J., et al.
Publicado: (2019)

Exercise in Multiple Sclerosis: Knowing is Not Enough—The Crucial Role of Intention Formation and Intention Realization
por: Schüler, Julia, et al.
Publicado: (2019)

Human ES cell-derived dendritic cells: Meeting the challenge of immune rejection in allogeneic cell therapy
por: Zenke, Martin
Publicado: (2020)

Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer
por: Liu, Xiaoming, et al.
Publicado: (2017)

Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
por: Gao, Xin, et al.
Publicado: (2019)

Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas
por: Uckun, Fatih M., et al.
Publicado: (2018)

Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes
por: Uckun, Fatih M., et al.
Publicado: (2023)

CD22 Exon 12 Deletion as an Independent Predictor of Poor Treatment Outcomes in B-ALL
por: Qazi, Sanjive, et al.
Publicado: (2023)

Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies
por: Kerepesi, Csaba, et al.
Publicado: (2020)

The therapeutic potential of immune cell-derived exosomes as an alternative to adoptive cell transfer
por: Hong, Yeonsun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2tje4bqnghc758neioopupvnh0